Market closedNon-fractional
VBI Vaccines/VBIV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About VBI Vaccines
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Ticker
VBIV
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
135
Website
www.vbivaccines.com
VBI Vaccines Metrics
BasicAdvanced
$22M
Market cap
-
P/E ratio
-$4.30
EPS
1.89
Beta
-
Dividend rate
Price and volume
Market cap
$22M
Beta
1.89
Financial strength
Current ratio
0.34
Quick ratio
0.165
Long term debt to equity
-20.779
Total debt to equity
-927.602
Interest coverage (TTM)
-5.63%
Management effectiveness
Return on assets (TTM)
-29.15%
Return on equity (TTM)
-419.59%
Valuation
Price to revenue (TTM)
1.559
Price to book
-3.33
Price to tangible book (TTM)
-0.43
Price to free cash flow (TTM)
-0.285
Growth
Revenue change (TTM)
553.09%
Earnings per share change (TTM)
-69.13%
3-year revenue growth
115.00%
3-year earnings per share growth
-15.19%
What the Analysts think about VBI Vaccines
Analyst Ratings
Majority rating from 1 analysts.
VBI Vaccines Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.2M
50.00%
Net income
-$18M
-∞%
Profit margin
-1,491.66%
-∞%
VBI Vaccines News
AllArticlesVideos
VBI Vaccines Announces Results of Annual General Meeting
Business Wire·2 weeks ago
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Business Wire·3 months ago
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for VBI Vaccines stock?
VBI Vaccines (VBIV) has a market cap of $22M as of July 06, 2024.
What is the P/E ratio for VBI Vaccines stock?
The price to earnings (P/E) ratio for VBI Vaccines (VBIV) stock is 0 as of July 06, 2024.
Does VBI Vaccines stock pay dividends?
No, VBI Vaccines (VBIV) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next VBI Vaccines dividend payment date?
VBI Vaccines (VBIV) stock does not pay dividends to its shareholders.
What is the beta indicator for VBI Vaccines?
VBI Vaccines (VBIV) has a beta rating of 1.89. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell VBI Vaccines stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.